Last reviewed · How we verify
Symbicort Turbuhaler
Symbicort Turbuhaler is a combination of budesonide, an inhaled corticosteroid, and formoterol, a long-acting beta2-adrenergic receptor agonist, used to control symptoms of asthma and chronic obstructive pulmonary disease (COPD).
Symbicort Turbuhaler is a combination of budesonide, an inhaled corticosteroid, and formoterol, a long-acting beta2-adrenergic receptor agonist, used to control symptoms of asthma and chronic obstructive pulmonary disease (COPD). Used for Maintenance and control of asthma symptoms, Maintenance and control of symptoms in COPD.
At a glance
| Generic name | Symbicort Turbuhaler |
|---|---|
| Also known as | Symbicort Turbuhaler 160/4.5 microg |
| Sponsor | Orion Corporation, Orion Pharma |
| Drug class | Inhaled corticosteroid and long-acting beta2-adrenergic receptor agonist combination |
| Target | Beta2-adrenergic receptor |
| Modality | Small molecule |
| Therapeutic area | Respiratory |
| Phase | Phase 3 |
Mechanism of action
Budesonide works by reducing inflammation in the lungs, while formoterol helps to relax the airway muscles, making it easier to breathe. This combination allows for improved control of symptoms and reduced risk of exacerbations.
Approved indications
- Maintenance and control of asthma symptoms
- Maintenance and control of symptoms in COPD
Common side effects
- Oral thrush
- Headache
- Cough
- Pharyngitis
- Dysphonia
Key clinical trials
- Ventilation and Perfusion in Asthmatics (PHASE4)
- A Study to Investigate How Budesonide and Formoterol Move Through the Body (Pharmacokinetics) When Delivered With Different Devices in Participants Aged 4 to Less Than 12 Years Old With Asthma (PHASE1)
- Open-label Study to Assess Reduction of Background Asthma Medication While Sustaining Asthma Control and Clinical Remission With Tezepelumab in Patients 12-80yrs With Severe Asthma. (PHASE3)
- A 24-Week Efficacy and Safety Study to Assess Budesonide and Formoterol Fumarate Metered Dose Inhaler in Adult and Adolescent Participants With Inadequately Controlled Asthma (VATHOS) (PHASE3)
- Anti-Inflammatory Reliever South Africa (PHASE3)
- Symptom-driven ICS/LABA Therapy for Adolescent Patients With Asthma Non-adherent to Daily Maintenance Inhalers (PHASE1, PHASE2)
- Study to Assess PT010 in Adult and Adolescent Participants With Inadequately Controlled Asthma (KALOS) (PHASE3)
- Individualizing Treatment for Asthma in Primary Care (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Symbicort Turbuhaler CI brief — competitive landscape report
- Symbicort Turbuhaler updates RSS · CI watch RSS
- Orion Corporation, Orion Pharma portfolio CI